Press Releases

Prior announcements are available on the ASX website.

October 11, 2018
ResApp Announces Positive Results from Prospective Sleep Apnoea Clinical Study

October 2, 2018
ResApp Completes Recruitment in Prospective Sleep Apnoea Study

September 27, 2018
ResApp Provides Update on SMARTCOUGH-C-2 Study Timing

September 19, 2018
ResApp Successfully Completes $7.5 Million Capital Raising

September 3, 2018
ResApp Announces Positive Top-line Results from Australian Prospective Paediatric Clinical Study

August 16, 2018
ResApp Partners with Lockheed Martin for U.S. Government Agency Research Program

August 15, 2018
ResApp Receives Notice of Acceptance for Core Patent in Australia

August 2, 2018
ResApp Completes Enrolment in Australian Paediatric Clinical Study

August 1, 2018
ResApp Completes Enrolment in SMARTCOUGH-C-2 Study

July 12, 2018
ResApp Provides Obstructive Sleep Apnoea Study Update

June 28, 2018
ResApp Provides Update on Australian Clinical Study

June 6, 2018
ResApp Receives Notice of Allowance for Core Patent in US

May 31, 2018
ResApp Provides SMARTCOUGH-C-2 Study Update

April 26, 2018
ResApp Receives R&D Tax Incentive Cash Rebate for FY17

April 24, 2018
ResApp Signs LOI with German Private Hospital Network for Pilot Project

April 10, 2018
ResApp Announces Development of Obstructive Sleep Apnoea Screening Test

March 9, 2018
ResApp Provides SMARTCOUGH-C-2 Study Update

January 11, 2018
ResApp Receives Third Institutional Review Board Approval for SMARTCOUGH-C-2 Study

January 8, 2018
ResApp Enrols First Patient in SMARTCOUGH-C-2 Study

December 29, 2017
ResApp Appoints Non-Executive Director

December 19, 2017
ResApp Receives Institutional Review Board Approval at Massachusetts General Hospital for SMARTCOUGH-C-2 Study

December 18, 2017
ResApp Announces Further Positive Results from Australian Adult Clinical Studies

December 13, 2017
ResApp Receives Institutional Review Board Approval at Texas Children’s Hospital for SMARTCOUGH-C-2 Study

September 14, 2017
Update on Field Evaluation by Médecins Sans Frontières/Doctors Without Borders

September 4, 2017
SMARTCOUGH-C Study and Paediatric Clinical Strategy Update

August 23, 2017
Dr Philip Currie Joins ResApp’s Scientific Advisory Board

August 21, 2017
ResApp Receives R&D Tax Incentive Cash Refund for FY16

August 9, 2017
ResApp Reports Preliminary Top-line Results from SMARTCOUGH-C Study for Diagnosis of Childhood Respiratory Disease using Cough Sounds

June 22, 2017
ResApp Provides Updated Australian Paediatric Study Results

June 19, 2017
ResApp Announces Completion of Enrolment in SMARTCOUGH-C Study

May 30, 2017
ResApp Provides SMARTCOUGH-C May Study Update

May 9, 2017
ResAppDx to be Formally Evaluated by Médecins Sans Frontières/Doctors Without Borders in a Low Income Setting

April 28, 2017
ResApp Licenses Additional Pneumonia Diagnostic Tool from UniQuest

April 19, 2017
ResApp Extends SMARTCOUGH-C Study

March 21, 2017
ResApp to Present at Upcoming Conferences in March

March 15, 2017
ResApp Provides SMARTCOUGH-C Study Update

January 10, 2017
ResApp Announces Expanded Research Collaboration with Massachusetts General Hospital

December 9, 2016
ResApp Initiates SMARTCOUGH-C Study Evaluating Efficacy of ResAppDx for Diagnosing Childhood Respiratory Disease

November 28, 2016
ResApp to Present at Wilsons Healthcare IT Conference

November 16, 2016
ResApp Receives Institutional Review Board Approval at Texas Children’s Hospital for SMARTCOUGH-C Study

November 11, 2016
ResApp Receives Institutional Review Board Approval at Massachusetts General Hospital for SMARTCOUGH-C Study

October 25, 2016
ResApp Receives Australian Emerging Company of the Year Award at the “Johnson & Johnson Innovation Industry Excellence Awards”

October 21, 2016
ResApp Receives First Institutional Review Board Approval for SMARTCOUGH-C Study

October 12, 2016
ResApp Wins Innovation Excellence Award at Tech23 2016

October 3, 2016
ResApp Announces Further Positive Results from Adult Clinical Study

September 15, 2016
ResApp Begins Field Evaluation with Leading Global Humanitarian Organisation

August 19, 2016
ResApp Wins Global Grand Finals at the 2016 Talent Unleashed Awards

August 18, 2016
ResApp Expands Diagnostic Application to the Management of Respiratory Disease

July 22, 2016
ResApp Wins Category at the 2016 Talent Unleashed Awards

July 20, 2016
ResApp Announces Massachusetts General Hospital as First US Clinical Study Site

June 30, 2016
ResApp Provides Update on US Clinical Study

June 21, 2016
ResApp Announces Positive Preliminary Results from Adult Clinical Study

June 7, 2016
ResApp Provides Australian Adult Study Enrolment Update

April 20, 2016
ResApp Completes Oversubscribed $12.5 Million Capital Raising to Expand Market Opportunity

March 31, 2016
ResApp Provides Updated Paediatric Clinical Study Results

March 14, 2016
ResApp Completes Successful Pre-Submission Meeting with the US FDA

March 7, 2016
ResApp Collaborates with Leading Humanitarian Organisation to Field Test ResApp’s Smartphone-Based Pneumonia Diagnostic in the Developing World

March 2, 2016
ResApp Achieves Breakthrough Performance in Paediatric Clinical Study

February 26, 2016
Second Site Added to Adult Clinical Study

January 22, 2016
ResApp to Exhibit at the McKinsey Future of Digital Healthcare Conference in Dubai

MEDIA INQUIRIES
Brian Leedman
VP, Corporate Affairs
+61 412 281 780
brian@resapphealth.com.au

ResApp Logo White

ResApp Health Limited
ABN 51 094 468 318
Headquarters: Level 8, 127 Creek St, Brisbane, QLD 4000
Registered Office: Level 24, 44 St Georges Tce, Perth, WA 6000

© 2018 ResApp Health Limited. All Rights Reserved.

CONTACT US
+61 8 6211 5099
+61 8 9218 8875
General Information
Clinical Studies
Investor Relations

    

LEGAL
Terms of Use
Privacy Policy

ResApp Health®, the ResApp Health logo and ResAppDx® are registered trademarks of ResApp Health Limited in the United States.

In the United States, ResAppDx is an investigational device and is not available for sale.